Saroglitazar

DB13115InvestigationalSmall molecule

Saroglitazar has been investigated for the treatment of Fatty Liver.

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor alpha and Peroxisome proliferator-activated receptor gamma
Curator reviewed
Formula / weight: C₂₅H₂₉NO₄S · 439.57 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyMRWFZSLZNUJVQW-DEOSSOPVSA-NSMILESCCO[C@@H](CC1=CC=C(OCCN2C(C)=CC=C2C2=CC=C(SC)C=C2)C=C1)C(O)=O

Targets

What you can answer from here — as of September 05, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

19Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Saroglitazar, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.